Literature DB >> 27383187

Disclosure UK: transparency should no longer be an optional extra.

Kate Adlington1, Fiona Godlee2.   

Abstract

Mesh:

Year:  2016        PMID: 27383187     DOI: 10.1136/bmj.i3730

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  4 in total

1.  Are conflict of interest declarations appropriate to allow sufficient consideration of potential bias in presentations?

Authors:  William Crawford; C Fielder Camm; Ishika Prachee; Jack Olivarius-McAllister; Matthew R Ginks; Edward D Nicol
Journal:  Future Healthc J       Date:  2020-10

Review 2.  Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.

Authors:  Piotr Ozieranski; Luc Martinon; Pierre-Alain Jachiet; Shai Mulinari
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

3.  Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.

Authors:  Shai Mulinari; Piotr Ozieranski
Journal:  BMJ Open       Date:  2018-10-21       Impact factor: 2.692

4.  Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians.

Authors:  Anju Murayama; Yuki Senoo; Kayo Harada; Yasuhiro Kotera; Hiroaki Saito; Toyoaki Sawano; Yosuke Suzuki; Tetsuya Tanimoto; Akihiko Ozaki
Journal:  Int J Environ Res Public Health       Date:  2022-03-15       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.